BioSpace News Archive

ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, announced the appointment of Marty Lorenzo as General Counsel.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca.

Intensity Therapeutics, Inc. today announced that new breast cancer data from its phase 1/2 study IT-01 using novel lead asset, INT230-6, will be presented at the San Antonio Breast Cancer Symposium (SABCS) being held virtually and in-person at the Henry B. Gonzales Convention Center in San Antonio, Texas from December 7-10, 2021.

Dr. Michael B. McDonnell hired as Chief Medical Officer, Dr. Jeffrey Sprouse as Director of Pipeline Development, Jamie Jarecki-Smith as Director of Clinical Operations and Dr. Nancy Raimondi as Director of Intellectual Property.

Blade Therapeutics, Inc. today announced positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF.

Virtual Incision Corporation, a medical device company pioneering first-of-its-kind miniaturized robots for laparoscopic surgery, announced it has raised $46 million in a Series C funding round.

Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of BRIMOCHOL for the Treatment of Presbyopia.

Cybin Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has authorized an investigator-initiated randomized, placebo-controlled Phase 2 clinical trial evaluating psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress.

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit.

Spectral Medical Inc. and its wholly-owned subsidiary Dialco Medical Inc., announced that it will host a conference call at 2:00 PM EST on Thursday, December 2, 2021, to provide a clinical update and discuss the latest business developments.